Marinus Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Marinus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Marinus Pharmaceuticals: 19 sponsored US clinical trials, none currently recruiting.
Marinus Pharmaceuticals sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 6 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Drug Resistant Partial Onset Seizure, with 1 trials.
Top-decile sponsor footprint
Marinus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
NCT05604170
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
NCT05323734
Randomized Therapy In Status Epilepticus
NCT04391569
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
NCT04285346
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
NCT03865732
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
NCT03572933
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
NCT03350035
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
NCT03460756
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
NCT03228394
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
NCT02358538
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
NCT02519439
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
NCT01963208
Ganaxolone Treatment in Children With Fragile X Syndrome
NCT01725152
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
NCT01339689
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
NCT01002820
Open-label Extension to Protocol 1042-0600
NCT00512317
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
NCT00465517
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
NCT00441896
Open-label Extension to Protocol 1042-0500
NCT00442104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 13 |
| Phase 3 | 6 |
Therapeutic Areas
How the Marinus Pharmaceuticals early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 16 completed (84%).
Phase mix: 6 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Drug Resistant Partial Onset Seizure (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Marinus Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Marinus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Marinus Pharmaceuticals page
19 registered trials is a research-attention snapshot, not an endorsement of Marinus Pharmaceuticals or any single study.
- None of Marinus Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Drug Resistant Partial Onset Seizure is the condition Marinus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Drug Resistant Partial Onset Seizure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Marinus Pharmaceuticals pipeline card: 19 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.